FHL2 facilitates LUSC growth and therapy resistance through PI3K/AKT/mTOR activation
L
Lingxian Zhang
D
Dingguo Wang
L
Lei Zeng
S
Shiwei Chen
K
Kunchao Li
T
Tiankai Yuan
J
Jing Wang
(Hunan Cancer Hospital Changsha China)
X
Xiong Ma
S
Shuqiang Zhu
Y
Yongbing Wu
Article Details
Journal
Journal of Biological Chemistry
Volume / Issue
Vol. 301, Issue 7
Published
July 01, 2025
Pages
110332
ISSN
0021-9258
Publisher
Elsevier BV
Authors (10)
L
Lingxian Zhang
D
Dingguo Wang
L
Lei Zeng
S
Shiwei Chen
K
Kunchao Li
T
Tiankai Yuan
J
Jing Wang
Hunan Cancer Hospital Changsha China
X
Xiong Ma
S
Shuqiang Zhu
Y
Yongbing Wu
Related Articles from this Journal
Asialoglycoprotein receptor subunit Asgr1a loss results in attenuated cholesterol absorption in zebrafish fed a western diet
Joshua T. Derrick, Tabea O.C. Moll et al.
Aug 2026
10.1016/j.jbc.2026.113239
Nrf2-mediated epigenetic priming of osmoprotective genes enhances cellular adaptation to hyperosmotic stress
Yi Lu, Na Li et al.
Aug 2026
10.1016/j.jbc.2026.113278
Saturated cardiolipins are potent disruptors of inner mitochondrial membrane structure and function
Kailash Venkatraman, Daniel Milshteyn et al.
Aug 2026
10.1016/j.jbc.2026.113306
Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression
Katerina-Marina Pilala, Artemis-Melina Papadimitriou et al.
Aug 2026
10.1016/j.jbc.2026.113302
Correction: Abstract 5588 Multifunctional carbon dots nanocarriers: Dual-drug delivery via π-π stacking interaction for stimuli-responsive chemotherapy and high oxidative stress
Girum Demissie, Jia Chang
Aug 2026
10.1016/j.jbc.2026.113253